Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to
reduce platelet reactivity and to prevent thrombotic events in patients treated with …

Antithrombotic drugs, which include antiplatelet and anticoagulant therapies, prevent and
treat many cardiovascular disorders and, as such, are some of the most commonly …

Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …

5. Leczenie.............................................................. 1225 5.1. Farmakoterapia
niedokrwienia...................... 1225 5.1. 1. Ogólne leczenie objawowe................. 1225 5.1. 2 …

Zachęca się pracowników opieki zdrowotnej, aby w pełni uwzględniali te wytyczne
ESC/EACTS, gdy dokonują oceny klinicznej, a także kiedy określają i realizują medyczne …

Background The relation between platelet reactivity and stent thrombosis, major bleeding,
and other adverse events after coronary artery implantation of drug-eluting stents has been …

Light transmission aggregometry (LTA), which was independently developed in 1962 by
Born 1 and O'Brien 2, is considered the gold standard for testing platelet function, because it …

Background During the last 30 years, the median sample size of research studies published
in high-impact medical journals has increased manyfold, while the use of non-parametric …

Optimizing outcomes after percutaneous coronary intervention (PCI) requires balancing
between the risks of thrombotic and bleeding events in individual patients. 1–3 However …

Background Prospective assessment of pharmacogenetic strategies has been limited by an
inability to undertake bedside genetic testing. The CYP2C19* 2 allele is a common genetic …